About Splenz Pharmaceuticals Private Limited
Data last updated:
Splenz Pharmaceuticals Private Limited is a private limited company based in Pune, Maharashtra, India. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 27 May 2014 and has been in existence for over 12 years.
The company is registered with the Registrar of Companies (ROC), Pune, under CIN U52599PN2014PTC151314. Its GSTIN is 27AAUCS6010M1ZT (Maharashtra).
The company has an authorised share capital of ₹20 Lakh and a paid-up capital of ₹20 Lakh. It is led by directors Ashish Bhagwan Bhagat and Jitendra Ashok Fasate.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at S. No. 1095 Milkat. No. 3672 Near Sakal Press Trimurti Nagar Wadki, Pune, Maharashtra, India – 412308.
As per the financials filed for FY 2024, the company reported a revenue of ₹2.66 Cr, a growth of 21% compared to the previous year. For the same year it recorded a net profit of ₹7.36 Lakh (net margin 2.8%) and EBITDA of ₹18.2 Lakh (EBITDA margin 6.8%). Revenue has grown at a compounded annual rate (CAGR) of 20% over three years and 8% over five years.
As per MCA filings, the company has open charges of ₹59.9 Lakh and satisfied charges of ₹50 Lakh on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website splenzpharma.com.
- EmailLocked
- TelephoneLocked
- Website
- Social MediaLocked
- Registered AddressS. No. 1095 Milkat. No. 3672 Near Sakal Press Trimurti Nagar Wadki, Pune, Maharashtra, India – 412308
- IndustryPharma, Pharmaceutical Retailers & Distributors
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Splenz Pharmaceuticals Private Limited
The main business activity of Splenz Pharmaceuticals is manufacturing. In detail, this covers manufacture of basic pharmaceutical products and pharmaceutical preparations.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | 21 | Manufacture of basic pharmaceutical products and pharmaceutical preparations | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Splenz Pharmaceuticals Private Limited FY 2025 filings available
Splenz Pharmaceuticals Private Limited reported revenue of ₹2.66 Cr (up 21% YoY) for FY 2024.
Compounded Annual Growth Rate (CAGR) of Splenz Pharmaceuticals Private Limited
Revenue has grown at a compounded annual rate (CAGR) of 8% over five years, including 21% growth in the latest year. EBITDA rose 33% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Splenz Pharmaceuticals Private Limited
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹18.2 Lakh | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹7.36 Lakh | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Splenz Pharmaceuticals Private Limited
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 6.8% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 2.8% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Splenz Pharmaceuticals are in the company report.
Financial statements from 2015
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Splenz Pharmaceuticals Private Limited
Splenz Pharmaceuticals Private Limited is compared with the companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Rangwani Pharmaceuticals Private Limited | ₹2.67 Cr (FY 2024) | •••• | •••• | 16.0% | •••• | Bhopal, Madhya Pradesh, India |
| Hillord Pharmaceutical India Private Limited | ₹2.67 Cr (FY 2018) | •••• | •••• | 99.0% | •••• | Namakkal, Tamil Nadu, India |
| Unixcel Pharmaceutical Private Limited | ₹2.67 Cr (FY 2025) | •••• | •••• | 33.0% | •••• | Khalapur, Maharashtra, India |
| Arke Formulations Private Limited | ₹2.66 Cr (FY 2025) | •••• | •••• | -8.0% | •••• | Rajkot, Gujarat, India |
| Evoxcare Pharmaceuticals Private Limited | ₹2.66 Cr (FY 2025) | •••• | •••• | 59.0% | •••• | Mohali, Punjab, India |
| Splenz Pharmaceuticals Private Limited this company | ₹2.66 Cr (FY 2024) | •••• | •••• | 21.0% | •••• | Pune, Maharashtra, India |
| Regbex Life Sciences Private Limited | ₹2.66 Cr (FY 2025) | •••• | •••• | 10.0% | •••• | Salem, Tamil Nadu, India |
| Xcelent Pharmaceuticals Private Limited | ₹2.66 Cr (FY 2025) | •••• | •••• | 86.0% | •••• | Noida, Uttar Pradesh, India |
| Neovant Therapeutics Private Limited | ₹2.66 Cr (FY 2025) | •••• | •••• | -71.0% | •••• | Mehsana, Gujarat, India |
| Chethana Medicaments Pvt Ltd | ₹2.65 Cr (FY 2025) | •••• | •••• | 11.0% | •••• | Malappuram, Kerala, India |
| QXP Pharma Project and GMP Services Private Limited | ₹2.65 Cr (FY 2025) | •••• | •••• | 190.0% | •••• | Sanand, Gujarat, India |
Peers are the five companies nearest above and the five nearest below Splenz Pharmaceuticals by revenue in the Pharma industry (Formulations, Pharmaceuticals), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Splenz Pharmaceuticals Private Limited
Splenz Pharmaceuticals Private Limited is audited by Amit G Malu & Associates for the financial year 2022.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| Amit G Malu & Associates | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Splenz Pharmaceuticals Private Limited
Splenz Pharmaceuticals has 2 current directors and 5 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Ashish Bhagwan Bhagat | Director | 23 Sep 2015 | 11 Years 0 Months | Current |
| Jitendra Ashok Fasate | Director | 23 Sep 2015 | 11 Years 0 Months | Current |
Ownership and Shareholding of Splenz Pharmaceuticals Private Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Splenz Pharmaceuticals Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 03 Jan 2020 | The South Indian Bank Limited | ₹59.9 Lakh | Open |
| 06 Dec 2014 | Others | ₹50 Lakh | Satisfied |
Total charge records: 2 View all charges
Employees and EPFO Compliance at Splenz Pharmaceuticals Private Limited
Employment history and EPFO contributions of people linked to Splenz Pharmaceuticals.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Splenz Pharmaceuticals Private Limited
Splenz Pharmaceuticals Private Limited has 7 board changes on record since 2015: 2 appointments and 5 cessations. The latest: Shylaja Padmakumar ceased to be Director on 31 Mar 2021.
3 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Splenz Pharmaceuticals Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Splenz Pharmaceuticals Private Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Splenz Pharmaceuticals Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Splenz Pharmaceuticals Private Limited
Splenz Pharmaceuticals has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAUCS6010M1ZT | Maharashtra | Active | 01 Jul 2017 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Splenz Pharmaceuticals Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Splenz Pharmaceuticals Private Limited
Splenz Pharmaceuticals is an active private limited company based in Pune, Maharashtra, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 27 May 2014 (12+ years old) and is registered under CIN U52599PN2014PTC151314.
Splenz Pharmaceuticals reported revenue of ₹2.66 Cr for FY 2024 (up 21% YoY).
Splenz Pharmaceuticals has 2 current directors:
- Ashish Bhagwan Bhagat - Director
- Jitendra Ashok Fasate - Director
Splenz Pharmaceuticals reported a net profit of ₹7.36 Lakh (net margin 2.8%) and EBITDA of ₹18.2 Lakh (EBITDA margin 6.8%) for FY 2024, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Splenz Pharmaceuticals is 20% over three years and 8% over five years. In the latest year (FY 2024) revenue rose 21%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Splenz Pharmaceuticals is 27AAUCS6010M1ZT, registered in Maharashtra.
The CIN (Corporate Identification Number) of Splenz Pharmaceuticals is U52599PN2014PTC151314. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Splenz Pharmaceuticals was incorporated on 27 May 2014, making it 12+ years old. It is registered with the Registrar of Companies, Pune.
The peers of Splenz Pharmaceuticals by revenue are Rangwani Pharmaceuticals Private Limited, Hillord Pharmaceutical India Private Limited, Unixcel Pharmaceutical Private Limited, Arke Formulations Private Limited, Evoxcare Pharmaceuticals Private Limited and 5 more, all in the Pharma industry (Formulations, Pharmaceuticals).
Shylaja Padmakumar ceased to be Director on 31 Mar 2021. Padmakumar Poduvattil ceased to be Director on 21 Aug 2020. Kumaranand Shankar Kulshrestha ceased to be Additional Director on 30 Sep 2017. Splenz Pharmaceuticals has 7 board changes on record in total.
Splenz Pharmaceuticals can be reached through the website splenzpharma.com. Its registered office is in Pune, Maharashtra, India.